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Summary Engineering of a variety of rodent tumour cells to secrete either interleukin 2 (IL-2), or interleukin
4 (IL-4), has been demonstrated to reduce their tumorigenicity. However the mechanisms of action of secreted
IL-2 and IL-4 have not been compared in a single rodent tumour. Here we demonstrate that the weakly
immunogenic murine fibrosarcoma FS29 had reduced growth rate and in some cases was rejected by syngeneic
animals, when modified to secrete either IL-2 or IL-4, but not IL-5. Immunohistochemical analysis of tumour
nodules undergoing regression showed stimulation of a largely lymphocytic infiltrate by IL-2 and a macro-
phage and granulocyte infiltrate, with a small number of lymphocytes by IL-4. Indeed, secretion of low levels
of IL-2 and IL-4 in combination resulted in optimal rejection, suggesting that the two cytokines might
mobilise different and complementary effector cell mechanisms. Both IL-2 and IL-4-secreting cells failed to
induce the rejection of admixed, unmodified FS29 cells. The loss of cytokine secreting cells from such
admixtures occurred more rapidly for IL-2-secreting cells. Injection of IL-4-secreting, but not IL-2-secreting
FS29 cells could protect mice from a delayed challenge with unmodified FS29 cells. These data suggest that
IL-4 secretion stimulates the better long-term host anti-tumour response.
Observations that rodents from which a primary, syngeneic
tumour had been excised could be resistant to a secondary
tumour challenge (Prehn & Main, 1957; Klein et al., 1960)
led to the proposition that a specific host anti-tumour
immune response could be stimulated. Subsequent studies
have demonstrated that the stimulation of tumour specific
cytotoxic T lymphocytes (CTLs) (Boon et al., 1980; Brunner
et al., 1981) is important in eliciting tumour rejection in
rodent models (Uyttenhove et al., 1983). Several approaches
to the treatment of human tumours have aimed to boost
what may be a sub-optimal patient anti-tumour immune
response. The systemic administration of IL-2, a stimulatory
factor for many cells of the immune system (Smith, 1988), to
patients with metastatic melanoma and renal cell carcinoma,
showed some therapeutic effect (Rosenberg et al., 1989).
However, toxic side-effects were observed at the high concen-
trations required (Rosenberg et al., 1989). A further strategy
has been the use of irradiated patient tumour cells, rendered
more antigenic by viral infection, as a potential vaccine to
protect against metastases (Bohle et al., 1990). Viral infection
(Lindenmann & Klein, 1967; Kobayashi et al., 1969; Boone
& Blackman, 1972; Ito et al., 1990) or the expression of
recombinant viral antigens (Fearon et al., 1988; Sugiura et
al., 1988), or MHC molecules (Hui et al., 1984; Tanaka et
al., 1985; Wallich et al., 1985), has proved successful in the
enhancement of immunogenicity of rodent tumour cells.
To overcome the toxicity of systemic cytokine administra-
tion, the effect of engineering rodent tumour cells to secrete
cytokines locally has been examined. Secretion of IL-2
(Fearon et al., 1990; Gansbacher et al., 1990; Russell et al.,
1991; Ley et al., 1991), IL-4 (Tepper et al., 1989; Golumbek
et al., 1991), y-interferon ('y-IFN) (Watanabe et al., 1989;
Gansbacher et al., 1990; Esumi et al., 1991), tumour necrosis
factor-a (TNF-a) (Asher et al., 1991; Blankenstein et al.,
1991), granulocyte colony stimulating factor (Colombo et al.,
1991), or interleukin 7 (Hock et al., 1991; McBride et al.,
1992) by a variety of rodent tumour cells has been demon-
strated to reduce, or eliminate, their tumorigenicity in
syngeneic animals. For this observation to be exploited in the
treatment of human malignant disease, two approaches could
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be attempted. Firstly, in vivo cytokine gene delivery to estab-
lished tumours might lead to local cytokine secretion and
ultimate tumour rejection. Direct delivery of a foreign MHC
gene to tumour cells in situ is the basis of a currently
approved human gene therapy trial (Miller, 1992). As gene
delivery to all cells within a tumour will probably not be
feasible, cytokine secretion by some cells within a tumour
would have to lead to the rejection of adjacent, unmodified
cells for direct cytokine gene delivery to be effective. An
effect on the rejection of admixed, unmodified cells has been
reported for IL-2 (Gansbacher et al., 1990; Ley et al., 1991;),
IL-4 (Tepper et al., 1989; Golumbek et al., 1991) and TNF-a
(Asher et al., 1991)-secreting rodent tumour cells.
The second therapeutic use of cytokine-secreting tumour
cells would be as an injection post primary tumour excision,
to enhance the elimination of minimal residual disease. This
would require the culture of cells from resected tumour
material and their in vitro modification to secrete cytokines,
followed by re-injection. Another human gene therapy trial is
employing this approach with IL-2 and TNF-a-secreting
tumour cells (Rosenberg et al., 1992a; Rosenberg, 1992b). In
rodent tumour studies IL-2 (Gansbacher et al., 1990; Ley et
al., 1991), IL-4 (Golumbek et al., 1991) and y-IFN
(Watanabe et al., 1989; Gansbacher et al., 1990)-secreting
tumour cells have each been shown to induce protection
against parental tumour cell challenge. In order to determine
which of these therapeutic routes might be the more feasible,
we have compared the properties of IL-2 and IL-4-secreting
tumour cells in a single murine tumour, the transplantable
fibrosarcoma, FS29 (Eccles et al., 1980). We have demon-
strated that either IL-2, or IL-4-secreting cells show a poor
ability to induce the rejection of admixed parental cells. This
failure can be ascribed to a rapid loss of the secreting cells
from tumours. However, IL-4-secreting FS29 cells showed a
greatly enhanced ability to protect animals against subse-
quent parental tumour challenge, when compared with IL-2-
secreting, or parental cell injections.
Methods and materials
Cell lines
FS29 is a benzpyrene induced murine sarcoma cell line
(Eccles et al., 1980) that was grown in vitro as an adherent
monolayer in DMEM with 10% fetal calf serum (FCS).
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PA317 (Miller & Buttimore, 1986) and GP + envAM12
(Markowitz et al., 1988) amphotropic retroviral packaging
cell lines were grown as adherent monolayers in DMEM and
10% newborn calf serum. IL-2-dependent CTLL-2 (Gillis &
Smith, 1977) and IL-2-dependent, IL-4-responsive HT-2
(Lichtman et al., 1987) cells were grown in suspension in
RPMI with 10% FCS, 5 x 10-5 M mercaptoethanol, 2 mM
glutamine and 50 U ml-' recombinant human IL-2 (Euro-
cetus).
Tumorigenicity assays
Exponentially growing tumour cells were trypsinised and
counted, then washed, resuspended in phosphate buffered
saline (PBS) and injected subcutaneously in 100 p1 into each
flank of syngeneic C57bl or athymic (nu/nu) mice. Tumour
diameter was measured with calipers X2/week. Animals were
maintained under a barrier system in accordance with Insti-
tutional guidelines. Mice were killed if they showed signs of
widespread malignancy, or when tumours were greater than
1 cm diameter or ulcerating. For explantation, tumour
nodules were resected, macerated with crossed scalpels and
incubated on a magnetic stirrer in 0.1% trypsin and 0.02%
DNAse for I h. The cell suspension was washed, plated and
the adherent monolayer expanded. 106 cells were replated and
after 48 h, supernatant was harvested for cytokine assays and
DNA prepared from cells for Southern blot analysis.
Plasmids and recombinant retroviruses
The plasmid pZipNeoSV(X) (Cepko et al., 1984), pZip-
NeoSVIL-2 (Yamada et al., 1987), containing the human
IL-2 cDNA, pZipNeoSVIL-4, containing a murine IL-4
cDNA (which was constructed by ligating a series of syn-
thetic oligonucleotides to give an identical amino-acid
sequence to that produced by the published murine IL-4
cDNA (Lee et al., 1986)) and pZipNeoSVIL-5 containing the
murine IL-5 cDNA (Campbell et al., 1987) were transfected
by calcium phosphate precipitation into PA317 or GP + env-
AM12 packaging cell lines. G418 resistant colonies were
picked and assayed for recombinant retrovirus production
and absence of helper virus as described previously (Danos,
1991). Clones producing the highest titre of helper free,
recombinant virus were used to infect FS29 cells by overnight
incubation with the packaging cell supernatant, in the
presence of 8 yg ml-i polybrene. The plasmid pZipNeo-
MuIL-2 was constructed by ligating a blunt ended, BamHI-
linkered PstI/SspI fragment from pCDMuIL-2, encoding
murine IL-2, to pZipNeoSV(X); this was used to transfect
FS29 cells. G418 resistant FS29 colonies were picked and
assayed for cytokine secretion. Stability of cytokine secretion
was established by re-assay after at least 6 weeks of in vitro
culture. The in vitro growth rate for cytokine-secreting clones
was tested by plating 5 x I03 cells into 6 well plates and
counting wells daily for 7 days. Plating efficiencies were
assessed by plating 100 cells in an 80cm2 flask and counting
colonies after 7 days. All clones were tested for absence of
helper virus (Danos, 1991).
Cytokine bioassays
Supernatants were harvested and passed through a 0.21tm filter 48 h after plating 106 tumour cells. Serial dilutions, and
recombinant human IL-2 standards (Eurocetus) were added
to 96 well micro titre plates containing 5,000 CTLL cells per well in a final volume of 200 p1. After 16 h, the cells were
pulsed with 0.5tiCi 3H-thymidine and incorporation was
measured 4 h later. One U human IL-2 (Gillis & Smith, 1977) gives half maximal thymidine incorporation under these con-
ditions. Results are expressed as units of IL-2 produced by 106 cells per 48 h. Supernatants also containing IL-4 were
incubated with Hbl88 (5% hybridoma supernatant), an IL-4-
blocking antibody (Ohara & Paul, 1985) for 2 h prior to
testing. For IL-4 assays, serial dilutions and recombinant
murine IL-4 standards (Genzyme, UK) were added to 96 well
micro titre plates containing 5,000 HT-2 cells per well in a
final volume of 200 ttl. After 16 h, the cells were pulsed with
0.5yCi 3H-thymidine and incorporation was measured 4 h
later. Under these conditions 0.3 U IL-4 gives half maximal
thymidine incorporation. Results are expressed as units of
IL-4 produced by 106 cells per 48 h. Supernatants also con-
taining IL-2 were incubated with EPIOO (12.5Agml-'), an
anti-IL-2 blocking antiserum (New Brunswick Scientific, UK)
for 2 h prior to testing. IL-5 was measured as previously
described (Strath et al., 1985).
Table I Tumour formation and cytokine secretion by FS29 clones
Cytokine
secretion Tumour Explant
Clone units/lJ6 cells/48 h growth secretion
FS29Neo 0 38/38
FS29IL2.1 54400 2/12t 0
n = I
FS29IL2.2 18100 18/22* 7 (0-46)
n = 6
FS29muIL2.7 3000 8/8 87 (15-164)
n = 4
FS29IL4.1 99200 26/26 68900 (57200-75300)
n = 3
FS29IL4.2 74500 4/24t 70150 (62200-87200)
n = 3 FS29IL4.5 94500 8/10 nd
FS29IL4.IL2.b 7100(IL2) 0/lot nd
22044(IL4)
FS29IL5.1 5657 6/6 nd
Cumulative data on tumour formation by FS29 clones, following the injection
of 106cellsinC57blmice, arepresented. Cytokine secretion by FS29clones before
injection (first column), and after explantation oftumours greater than 0.5 cm in
diameter from C57bl mice between 16 and 73 days after injection (third column),
was measured as described in Materials and methods. FS29IL-2.1 and 2.2 secrete
human IL-2, FS29muIL-2.7 secretes murine IL-2, FS29IL-4.1, 4.2 and 4.5 secrete
murine IL-4, FS29IL-4.1.IL2.b secretes murine IL-4 and human IL-2, FS29IL5.1
secretes murine IL-5. tP<0.001; *P<0.05 compared to the growth ofFS29Neo
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Immunohistochemistry
Exponentially growing tumour cells were injected sub-
cutaneously into each flank of syngeneic mice, as for
tumorigenicity studies. Tumour nodules were removed at 4,
7, 11 and 14 days. Haematoxylin and eosin sections were
fixed in 10% formalin and embedded in paraffin wax. Sec-
tions from frozen tissue blocks were fixed in acetone, then
incubated for 1 h with primary rat monoclonal antibodies;
anti-CD4 GK1.5 (gift from Dr R. Zamoyska), anti-CD8
53-6.7 (Becton Dickinson), anti-IL-2 receptor 7D4 (gift from
Prof. T. Malek), anti-IL-4 receptor MI (gift from Immunex),
anti-CD45RA (B cell specific) 14.8 (gift from Dr J. Marvel),
washed with PBS, then incubated for 1 h with biotinylated
anti-rat IgG (Dako). The antigen antibody complexes were
detected by incubation with ABC complex conjugated HRP
(Dako) and development with DAB.
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Results
Growth ofcytokine-secreting FS29 tumours
In order to compare the effect of secretion of either IL-2 or
IL-4 on tumour growth in vivo, a panel of cell lines was
generated from the murine transplantable sarcoma FS29, by
infection with recombinant retroviruses carrying cytokine
cDNAs. To generate a control cell line, FS29Neo, FS29 cells
were infected with a retrovirus lacking a cDNA insert. Table
I details the level of human IL-2, murine IL-2, murine IL-4,
or murine IL-5 produced in vitro by cell clones, selected as
secretors of the highest levels of cytokine. Cytokine secretion
did not affect the growth rate of the clones in vitro and the
levels of cytokine secreted were unchanged following pro-
longed passage of the cell clones in culture (data not shown).
All clones expressed very low or undetectable levels of MHC
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Figure 1 Growth of cytokine secreting tumour cells. 106 exponentially growing tumour cells were injected subcutaneously into
C57bl mice. Tumour diameter was measured twice weekly. Growth for each tumour in a typical experiment is shown. *P<0.005
when tumour size at 16 days compared to FS29Neo by calculating the standard error of the difference between the means.
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class I antigens, in comparison to transfected HeLa cells
expressing Kb, when analysed by staining with the Y3 anti-Kb
antibody (data not shown).
The growth rate of cytokine secreting tumours in vivo,
following the subcutaneous injection of 106 cells in syngeneic
mice, was then monitored. Figure 1 shows a typical experi-
ment for each clone and a compilation of all experiments is
presented in Table I. FS29IL-2.1 which secreted the highest
level of IL-2, formed an initial tumour nodule which then
regressed completely in most animals. Those clones secreting
less IL-2, FS29IL-2.2 and FS29muIL-2.7 showed some delay
in growth compared to FS29Neo cells, but ultimately formed
tumours in -the majority of animals. Tumours which arose
from the IL-2-secreting cell clones were explanted, cultured
and assessed for their ability to secrete IL-2. In every case the
explanted tumour cells secreted considerably reduced, or no,
IL-2 (Table I). This could be attributed to a decrease in the
IL-2-encoding retroviral integrant in each case (Figure 5,
upper panel, track 4 and data not shown). Thus, a strong
selective pressure against both human and murine IL-2 secre-
tion in vivo resulted in rapid selection of cells within the
tumour which had lost the retroviral integrant. This selection
was not observed upon growth of FS29IL-2.1 in athymic
mice (Figure 5, upper panel, track 3).
The three IL-4-secreting FS29 clones also displayed slower
growth rates and reduced tumorigenicity in syngeneic mice
(Figure 1 and Table I). One clone, FS29IL-4.2, formed small
nodules and then regressed in most animals. Two further
clones, FS29IL-4.1 and FS29IL-4.S, formed small tumours
which persisted for prolonged periods, in contrast to the IL-2
secreting clones. When such persistent tumours were ex-
planted and their IL-4-secretion was measured, it was found
that they secreted unreduced levels of IL-4 (Table I) and
retained the IL-4 encoding retroviral integrant (Figure 5,
lower panel, track 5). In contrast to previous reports (Tepper
et al., 1989; Golumbek et al., 1991), IL-4 secretion did not
affect the growth rate of FS29 cells in athymic mice (data not
shown). IL-4 secretion, by murine plasmacytoma, adenocar-
cinoma or renal cell carcinoma cells had previously been
reported to induce an eosinophilic infiltrate in vivo (Tepper et
al., 1989; Golumbek et al., 1991), and anti-IL-5 antibodies
had been shown to partially restore the tumorigenicity of
IL-4-secreting cells (Tepper et al., 1992). Therefore, we
monitored the effect of secretion of IL-5, the major growth
factor for cells of the eosinophil lineage, upon FS29 tumour
formation. Figure 1 shows that IL-5 secretion did not cause
any slowing of tumour growth in syngeneic animals; no
eosinophil infiltrate was observed in IL-5-secreting tumours
(data not shown). To observe the effect of simultaneous IL-2
and IL-4 secretion, a doubly-transfected clone secreting sub-
optimal levels of both cytokines was isolated. Additional
secretion of IL-2, by the non-rejecting IL-4 secreting clone
IL-4.1, was able to induce tumour rejection (Table I). This
co-operative effect suggested that the two cytokines might act
by mobilisation of different effector mechanisms.
Host cells infiltrating cytokine-secreting FS29 tumours
To examine the host cells involved in the response to
cytokine-secreting FS29 cells, small tumour nodules were
excised and infiltrating host cells were examined mor-
phologically and by immunohistochemical staining. While
few host cells were present in the unmodified FS29 tumour
nodule, a pronounced lymphocytic infiltrate was present in
a b
d
Figure 2 Histopathology ofcytokine secreting tumours. Tumour nodules were excised 7 to 10 days after injection of: 106 FS29Neo
in C57bl mice (a), FS29IL-2.1 in C57bl mice (b), FS29IL-4.2 in C57bl mice (c), FS29IL-4.2 in nu/nu mice (d). Sections were stained
with haematoxylin and eosin and photographed at a magnification of 500 x.THERAPEUTIC EFFECTS OF IL-2 OR IL-4 SECRETING TUMOURS 299
Table II Characterisation of host cell infiltrate- in FS29 tumour
nodules
FS29Neo FS29IL2.1 FS29IL4.2
Haematoxylin and
eosin
PMN +- + + + + +
macrophages +- + + + +
lymphocytes +- + + + + +
Immunohisto-
chemistry
anti-CD4 +/- + +
anti-CD8 +- + + + + +
anti-B cell - + +
anti-IL2R - + + +
anti-IL4R - + + + +
A summary ofmorphological and immunohistochemical analysis of
tumour nodules, explanted between 7 and 14 days after injection of 106
FS29Neo, FS29IL-2.1 and FS29IL-4.2 cells in C57bl mice.
the IL-2-secreting tumours (Figure 2). The majority of these
cells were CD8 +, with some CD4 + cells and B cells (Table
II). In contrast, the IL-4-secreting tumours were charac-
terised by a macrophage and granulocyte infiltrate, with a
small number of CD8 + and CD4 + lymphocytes (Figure 2,
Table II). This inflammatory cell infiltrate was not observed
in IL-4-secreting tumour nodules from athymic animals
(Figure 2) and thus appears to be dependent on a T lym-
phocyte response.
Cytokine-secreting cells are selectively lostfrom tumours
To assess the potential of cytokine gene delivery to existing
tumours in vivo as a tumour therapy, the ability of cytokine-
secreting FS29 cells to induce rejection of admixed, un-
modified cells was measured. Figure 3 shows that neither
IL-2, nor IL-4-secreting FS29 cells caused any slowing of
growth of an equal number of admixed non-secreting FS29
cells. When the IL-2, or IL-4-secreting cells were present in a
10-fold excess, initial delay in the growth of the unmodified
cells was observed, but rapidly growing tumours eventually
formed in all animals (Figure 3). These data are in contrast
to several previous studies, which have demonstrated effective
induction of parental tumour rejection by admixture of 50%
IL-2 (Gansbacher et al., 1990; Ley et al., 1991), or IL-4-
secreting cells (Tepper et al., 1989; Golumbek et al., 1991).
To investigate the reason for this lack of effect of cytokine
secretion on adjacent unmodified FS29 cells, tumour nodules
were explanted soon after injection of IL-2 and parental cell
admixtures. When the level of IL-2 secretion from such
explanted cells was analysed, admixtures of IL-2-secreting
and parental cells were found still to secrete IL-2 after 7 days
in vivo growth (Figure 4). However, following 14 days of
tumour development, IL-2 secretion was lost (Figure 4). This
correlated with loss of IL-2-encoding retroviral DNA
sequences, which could be detected after 7 days but not
14 days tumour growth, in the explanted cells (Figure 5,
upper panel, tracks 5 and 6). Similar analysis of admixtures
of IL-4-secreting and parental cells demonstrated greatly
reduced IL-4 secretion after 14 days growth in vivo (Figure 4)
and undetectable IL-4-encoding retroviral DNA (Figure 5,
lower panel, track 8). A more rapid loss of IL-2-secreting
cells could be clearly observed in an admixture of IL-2 and
IL-4-secreting cells. IL-2 and IL-4 rates of secretion by
tumours explanted after 7 days were similar to the injected
cells (Figure 4); both IL-2 and IL-4 retroviral DNA could be
detected (Figure 5, upper panel, track 7 and lower panel,
track 9). However, following 14 days growth of the admix-
ture IL-2 secretion (Figure 4) and retroviral DNA sequence
(Figure 5, upper panel, track 8) were reduced, while IL-4
secretion (Figure 4) and retroviral DNA (Figure 5, lower
panel, track 11) were maintained. These data show that a
strong selective pressure against IL-2-secreting FS29 cells and
a slightly weaker selective pressure against IL-4-secreting
FS29 cells, results in their loss from cell admixtures. This
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Figure 3 Growth of admixtures of cytokine secreting and non-
secreting tumour cells. FS29IL-2.1 cells (a) or FS29IL-4.1 cells (b)
were mixed with FS29Neo at ratios of 1:1 (106 cytokine
secretors + 106 FS29Neo), and 10:1 (106 cytokine secretors + I05
FS29Neo), and injected into each flank of C57bl mice. As cont-
rols, mice were injected with 105 or 106 FS29Neo cells.
provides an explanation for the inability of such cytokine
secreting FS29 cells to induce rejection of admixed parental
cells. These data suggest that direct retroviral-mediated
cytokine gene delivery to tumour cells in vivo will not be able
to induce tumour rejection, even if delivery to over 50% of
cells within a tumour were feasible.
IL-4-secreting cells can protect animalsfrom parental tumour
challenge.
An alternative application of retroviral cytokine gene
delivery in cancer therapy would be the use of tumour cells,
cultured following primary lesion excision and infected with
cytokine-encoding retroviruses, as an injection to enhance
eradication of minimal residual disease. The efficacies of300 P.M. PATEL et al.
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Figure 4 Cytokine secretion of explanted tumours. C57bl mice
were injected with either 106 FS29IL-2.-1, 106 FS29IL-4.2, 106
FS29IL-2.1 + 106 FS29Neo, 106 FS29IL-4.2 + 106 FS29Neo, or
106 FS29IL-2.1 + 106 FS29IL-4.2 into each flank. Tumour
nodules were excised at 7 and 14 days and supernatant from cells
passaged in vitro was assayed for IL-2 (a) and IL-4 (b) activity.
parental, IL-2 and IL-4-secreting FS29 cells in the induction
of lasting protection of syngeneic mice against FS29 tumour
challenge were therefore compared. Figure 6 shows that
animals which had rejected the IL-4-secreting FS29 cell
primary tumour showed considerably delayed tumour incid-
ence, when challenged after 48 days with FS29Neo cells. Five
out of 13 of these animals survived tumour-free for over 30
days. In contrast, parental cell injection afforded no lasting
protection, confirming the weak basal immunogenicity of this
tumour (Figure 6). IL-2-secreting tumour cells also did not
protect animals against delayed parental cell challenge
(Figure 6). These data suggest that IL-4-secreting tumour
cells, while unable to induce a rapid enough immune res-
ponse to cause the rejection of admixed parental cells, can
stimulate an effective long-term anti-tumour response.
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Discussion
This study represents a detailed comparison of the effects of
IL-2 and IL-4 secreted by the same tumour. Secretion of a
sufficiently high level of IL-2 by FS29 cells resulted in
tumour rejection, whereas lower levels of secretion slowed
initial growth but resulted in the later appearance of rapidly
growing tumours. This could be explained by the loss of the
IL-2 transgene and thus IL-2 secretion by these outgrowing
cells, which suggests that a strong selective pressure against
IL-2 secretion occurred in syngeneic animals. Loss of
cytokine was observed with tumour cells secreting either
human, or murine IL-2. A similar selection against IL-2
secretion was previously observed in the rat tumour HSN
when passaged in syngeneic immunocompetent, but not
athymic, animals (Russell et al., 1991). In contrast, IL-4
secretion by FS29 cells resulted in either tumour rejection or
the appearance of slow growing tumours which retained the
IL-4 transgene and secreted IL-4. Thus, IL-4 secretion was
not subject to such a strong immune selection.
However, when either IL-2- or IL-4-secreting tumour cells
were admixed with unmodified tumour cells, the parental
tumours rapidly emerged. By analysing explanted tumour
nodules, it was determined that the IL-2-secreting cells were
lost from such admixtures after 14 days, and that IL-4-
secreting cells were greatly reduced in proportion at this time.
Thus, a weak immune selection against IL-4-secreting cells
does occur when they are admixed with unmodified cells.
This lack of rejection of admixed, unmodified cells is in
contrast to previous studies with other IL-2-secreting (Gans-
bacher et al., 1990; Ley et al., 1991) or IL-4-secreting
Figure 5 Southern blot of explanted tumours. Tenlg of Sacd
digested genomic DNA, or 1Opg Bam HI digested plasmid was
electrophoresed on an 0.8% agarose gel, transferred to nitrocel-
lulose and hybridised with labelled human IL-2 (upper panel) or
murine IL-4 (lower panel) cDNAs. a: pZipSVIL-2 plasmid (1)
giving the 5 kbp proviral integrant size, FS29Neo (2), FS29IL-2.1
in nu/nu mice, day 7 (3), FS29IL-2.1 day 70 (4), FS29Neo +
FS29IL-2.1 day 7 (5), FS29Neo + FS29IL-2.1 day 14 (6),
FS29IL-2.1 + FS29IL-4.2 day 7 (7), FS29IL-2.1 + FS29IL-4.2
day 14 (8). b: pZipSVIL-4 plasmid (1) showing the 4.1 kbp and
0.9 kbp proviral integrant bands, FS29Neo (2) showing genomic
IL-4 bands of 6.2, 4.6, 4.0, 2.2, and 0.75 kbp, FS29IL-4.2 in
nu/nu mice, day 7 (3), FS29IL-4.2 day 7 (4), FS29IL-4.2 day 32
(5), FS29IL-4.2 + FS29Neo day 7 (6), FS29IL-4.2 + FS29Neo
day 11 (7), FS29IL-4.2 + FS29Neo day 14 (8), FS29IL-
4.2 + FS29IL-2.1 day 7 (9), FS29IL-4.2 + FS29IL-2.1 day 11
(10), FS29IL-4.2 + FS29IL-2.1 day 14 (11).
(Golumbek et al., 1991; Tepper et al., 1989) tumour cells.
The level of cytokine secretion that we have achieved is
similar, or higher than that reported in these studies; perhaps
the difference can be attributed to a lower intrinsic
immunogenicity of the FS29 tumour. The strong selection of
cytokine secreting cells from an admixture implies specific,
local immune stimulation by such cells. Furthermore, these
data would argue against direct cytokine gene delivery to
tumours in situ as an effective therapy, with the efficiency of
currently available gene therapy techniques.
A more feasible therapeutic approach appears to be the
injection of cytokine secreting tumour cells. Animals which
had rejected IL-4-secreting FS29 cells were protected against
parental tumour when challenged after 48 days. IL-2-THERAPEUTIC EFFECTS OF IL-2 OR IL-4 SECRETING TUMOURS 301
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Figure 6 Growth of secondary challenge tumours. Mice were
inoculated with 106 FS29Neo, FS29IL-2.1 or FS29IL-4.2 cells.
Any tumours growing at 18 days were excised; all surviving mice,
and a control group, were rechallenged after 48 days, on the
opposite flank, with 106 FS29Neo and tumour growth monitored.
Animals with tumour of greater than 0.4 cm which was increasing
in size were considered tumour positive. Percentage of tumour
free mice is shown as a function of time. *P<0.05 when tumour
incidence compared with naive controls on day 30 using a two-
tailed Fisher's exact probability test.
secreting, or parental tumour injected animals showed no
protection after this period. From analysis of the host cell
infiltrate in tumour nodules undergoing rejection, IL-4 and
IL-2 were clearly stimulating different subsets of cells. IL-2
recruited largely CD8 + lymphocytes, whereas IL-4 stim-
ulated macrophages, granulocytes, and some lymphocytes.
Indeed, secretion of both IL-2 and IL-4 by the same cell led
to enhanced tumour rejection. The stimulation of an
inflammatory infiltrate by IL-4 has previously been reported
in a murine plasmocytoma (Tepper et al., 1989), murine
adenocarcinoma (Tepper et al., 1989) and murine renal cell
carcinoma (Golumbek et al., 1991). The importance of such
an infiltrate has been demonstrated by the inhibition of
tumour rejection in the presence of anti-granulocyte anti-
bodies (Tepper et al., 1992). However in previous studies
IL-4 slowed tumour growth, or led to tumour rejection in
immunodeficient animals where a similar infiltrate was
observed (Tepper et al., 1989; Tepper et al., 1992). As a
variety of cell types express receptors for IL-4 (Paul, 1991), a
direct effect of this cytokine on the growth of some tumours
may be possible. The effects of IL-4 in the FS29 model
depend on the presence of T lymphocytes as we did not
observe any slowing of tumour growth, or cell infiltrate, in
athymic animals. Thus, IL-4 stimulation of T cells recruits
inflammatory cells, perhaps by the stimulation of further
cytokine production.
While induction of protective immunity clearly requires T
cell stimulation, the inflammatory cell infiltrate may also be
crucial in the generation of an optimal response. A previous
study has demonstrated that IL-4-secreting renal carcinoma
cells protect against subsequent tumour challenge and can
cure animals pre-injected with a small number of parental
cells (Golumbek et al., 1991). However, another report des-
cribes a complete absence of induction of protection by
IL-4-secreting plasmacytoma cells (Tepper et al., 1992). Two
reports described lasting protection induced by IL-2-secreting
cells (Gansbacher et al., 1990; Ley et al., 1991), the work of
Ley et al. (Ley et al., 1991) demonstrated an enhanced
protection compared to parental mastocytoma cells. The
study of Fearon et al. described short-term protection
induced by IL-2-secreting colon tumour cells which is greatly
diminished after 28 days (Fearon et al., 1990). Such
differences observed in previous studies might be ascribed to
differential intrinsic immunogenicity of the various tumours.
Our direct comparison, in the FS29 sarcoma model, suggests
that IL-4-secreting cells provide the better protection. The
greater protective response induced by IL-4 may be partly
explained by two of our observations. Firstly, IL-4 recruits
different subsets of host immune cells, as demonstrated by
the different infiltrate observed in IL-4 compared with IL-2-
secreting tumours. Some of the cells recruited by IL-4, but
not by IL-2, may be important to the establishment of a
long-term anti-tumour response. Secondly, as IL-4-secreting
cells suffer a less stringent host immune selection, IL-4-
secreting tumour cells are maintained for longer than their
IL-2 counterparts. This longer period of immune stimulation
may also be important in the generation of a greater res-
ponse.
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